[
  {
    "ts": null,
    "headline": "Regeneron makes second bid for blood cancer therapy approval",
    "summary": "The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July 2025.",
    "url": "https://finnhub.io/api/news?id=a32b7c535439748056f6a16c7f873f63d0765a9f116474fd8ff4df4d0300653a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740658663,
      "headline": "Regeneron makes second bid for blood cancer therapy approval",
      "id": 133186700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July 2025.",
      "url": "https://finnhub.io/api/news?id=a32b7c535439748056f6a16c7f873f63d0765a9f116474fd8ff4df4d0300653a"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN",
    "summary": "NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=ea079fb578358a3abfb42f8fcad56095850797a55138b22a030de211f1df741f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740635180,
      "headline": "Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN",
      "id": 132898624,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=ea079fb578358a3abfb42f8fcad56095850797a55138b22a030de211f1df741f"
    }
  }
]